MacEwan JP - Search Results

1

The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.

MacEwan JP, Yin W, Kaura S, Khan ZM. MacEwan JP, et al. J Manag Care Spec Pharm. 2017 Feb;23(2):206-213. doi: 10.18553/jmcp.2017.23.2.206. J Manag Care Spec Pharm. 2017. PMID: 28125374

2

Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.

Stevens W, Philipson TJ, Khan ZM, MacEwan JP, Linthicum MT, Goldman DP. Stevens W, et al. Among authors: macewan jp. Health Aff (Millwood). 2015 Apr;34(4):562-70. doi: 10.1377/hlthaff.2014.0634. Health Aff (Millwood). 2015. PMID: 25847637

3

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.

Lakdawalla DN, Chou JW, Linthicum MT, MacEwan JP, Zhang J, Goldman DP. Lakdawalla DN, et al. Among authors: macewan jp. JAMA Oncol. 2015 May;1(2):196-202. doi: 10.1001/jamaoncol.2015.0203. JAMA Oncol. 2015. PMID: 26181023

4

Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.

MacEwan JP, Seabury S, Aigbogun MS, Kamat S, van Eijndhoven E, Francois C, Henderson C, Citrome L. MacEwan JP, et al. Innov Clin Neurosci. 2016 Aug 1;13(7-8):17-25. eCollection 2016 Jul-Aug. Innov Clin Neurosci. 2016. PMID: 27672484 Free PMC article.

5

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.

MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP. MacEwan JP, et al. J Manag Care Spec Pharm. 2016 Nov;22(11):1349-1361. doi: 10.18553/jmcp.2016.22.11.1349. J Manag Care Spec Pharm. 2016. PMID: 27783548

6

The value of survival gains in myelodysplastic syndromes.

MacEwan JP, Yin W, Kaura S, Khan ZM. MacEwan JP, et al. Am J Manag Care. 2017 Jan 1;23(1):e10-e15. Am J Manag Care. 2017. PMID: 28141936

7

Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.

Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. Jansen JP, et al. Among authors: macewan jp. J Med Econ. 2017 Jul;20(7):703-714. doi: 10.1080/13696998.2017.1307205. Epub 2017 Apr 5. J Med Econ. 2017. PMID: 28294642

8

The relationship between adherence and total spending among Medicare beneficiaries with type 2 diabetes.

MacEwan JP, Sheehan JJ, Yin W, Vanderpuye-Orgle J, Sullivan J, Peneva D, Kalsekar I, Peters AL. MacEwan JP, et al. Am J Manag Care. 2017 Apr;23(4):248-252. Am J Manag Care. 2017. PMID: 28554205

9

The importance of model inputs and assumptions in conducting health technology assessments of novel drugs.

Philipson T, MacEwan JP. Philipson T, et al. Among authors: macewan jp. J Med Econ. 2017 Oct;20(10):1107-1109. doi: 10.1080/13696998.2017.1359182. Epub 2017 Aug 4. J Med Econ. 2017. PMID: 28737052 No abstract available.

10

What do pharmaceuticals really cost in the long run?

Lakdawalla D, MacEwan JP, Dubois R, Westrich K, Berdud M, Towse A. Lakdawalla D, et al. Among authors: macewan jp. Am J Manag Care. 2017 Aug;23(8):488-493. Am J Manag Care. 2017. PMID: 29087143 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results